Chemotherapy Decision-Making in Early Breast Cancer

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.

Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.